X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs WOCKHARDT LTD. - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD WOCKHARDT LTD. STRIDES SHASUN LTD/
WOCKHARDT LTD.
 
P/E (TTM) x 37.2 -23.2 - View Chart
P/BV x 0.9 2.4 39.3% View Chart
Dividend Yield % 1.1 0.0 65,297.4%  

Financials

 STRIDES SHASUN LTD   WOCKHARDT LTD.
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
WOCKHARDT LTD.
Mar-18
STRIDES SHASUN LTD/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,2751,012 126.0%   
Low Rs918532 172.7%   
Sales per share (Unadj.) Rs389.6355.9 109.5%  
Earnings per share (Unadj.) Rs28.0-60.3 -46.4%  
Cash flow per share (Unadj.) Rs48.9-46.8 -104.6%  
Dividends per share (Unadj.) Rs4.500.01 45,000.0%  
Dividend yield (eoy) %0.40 31,676.7%  
Book value per share (Unadj.) Rs303.1257.8 117.6%  
Shares outstanding (eoy) m89.42110.63 80.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.2 129.8%   
Avg P/E ratio x39.2-12.8 -306.2%  
P/CF ratio (eoy) x22.4-16.5 -135.9%  
Price / Book Value ratio x3.63.0 120.8%  
Dividend payout %16.10 -96,985.3%   
Avg Mkt Cap Rs m98,03685,379 114.8%   
No. of employees `0005.86.3 92.7%   
Total wages/salary Rs m5,8819,371 62.8%   
Avg. sales/employee Rs Th6,005.96,295.0 95.4%   
Avg. wages/employee Rs Th1,014.01,498.3 67.7%   
Avg. net profit/employee Rs Th431.2-1,066.3 -40.4%   
INCOME DATA
Net Sales Rs m34,83439,369 88.5%  
Other income Rs m1,6861,202 140.2%   
Total revenues Rs m36,52040,571 90.0%   
Gross profit Rs m6,42818 35,125.7%  
Depreciation Rs m1,8721,495 125.2%   
Interest Rs m2,2692,555 88.8%   
Profit before tax Rs m3,973-2,830 -140.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006-3,582 28.1%   
Tax Rs m470257 182.9%   
Profit after tax Rs m2,501-6,669 -37.5%  
Gross profit margin %18.50 39,698.4%  
Effective tax rate %11.8-9.1 -130.2%   
Net profit margin %7.2-16.9 -42.4%  
BALANCE SHEET DATA
Current assets Rs m38,16533,796 112.9%   
Current liabilities Rs m30,40226,917 112.9%   
Net working cap to sales %22.317.5 127.5%  
Current ratio x1.31.3 100.0%  
Inventory Days Days7779 97.5%  
Debtors Days Days10489 117.1%  
Net fixed assets Rs m37,63939,664 94.9%   
Share capital Rs m894553 161.6%   
"Free" reserves Rs m26,21027,968 93.7%   
Net worth Rs m27,10528,522 95.0%   
Long term debt Rs m16,37721,731 75.4%   
Total assets Rs m81,16881,620 99.4%  
Interest coverage x2.8-0.1 -2,558.4%   
Debt to equity ratio x0.60.8 79.3%  
Sales to assets ratio x0.40.5 89.0%   
Return on assets %5.9-5.0 -116.6%  
Return on equity %9.2-23.4 -39.5%  
Return on capital %12.1-7.7 -157.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,4659,807 137.3%   
Fx outflow Rs m4,0761,789 227.9%   
Net fx Rs m9,3898,019 117.1%   
CASH FLOW
From Operations Rs m2,881684 421.0%  
From Investments Rs m-7,0516,302 -111.9%  
From Financial Activity Rs m3,382-7,695 -44.0%  
Net Cashflow Rs m-788-664 118.6%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 2.3 1,643.5%  
FIIs % 8.6 7.7 111.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 67,757 83.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - IPCA LABS COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS